Remix’s Co-Founder and CEO was recently featured in Pharmaceutical Technology, highlighting how modulating RNA processing can dramatically expand the universe of druggable targets.
Read the article by Jam Bensilum here: bit.ly/4aKtGdL
#REM422 #RNAdegradation #RNAdegraders #RNAtherapeutics
Today, we announced the appointment of Mythili Koneru, MD, PhD, as our Chief Medical Officer, leading clinical development, medical strategy, and regulatory engagement.
#mRNA #RNAdegradation #RNAdegraders #RNAtherapeutics #OncologyResearch #RemixTherapeutics
Read the PR here: bit.ly/4qJply4
📣 Remix Chief Scientific Officer, Dominic Reynolds, PhD, will be speaking at the Small Molecules Targeting RNA & DNA Conference during the Discovery on Target event in Boston Sept 23-24. #RNAtherapeutics #RNAdegraders #RNAdegradation #mRNA #OncologyResearch
